Dexcom Inc Financials
Dexcom Inc (DXCM) reported $4.7B in revenue for fiscal year 2025, up 15.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
DexCom is turning scale into cash as operating leverage and cash conversion improve despite lower gross margins.
Since FY2021, gross margin compressed by8.5% points while operating margin expanded by9.0% points, showing the profit engine improved below gross profit through overhead absorption rather than a richer gross-margin mix. That shift is visible in cash too: operating cash flow reached$1.44B in FY2025 versus net income of$836.3M , so reported earnings were reinforced by cash instead of thinning out after noncash and working-capital adjustments.
Capital intensity is easing. Capital spending stayed near
The balance sheet strengthened while cash was returned. Even after
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Dexcom Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Dexcom Inc has an operating margin of 19.6%, meaning the company retains $20 of operating profit per $100 of revenue. This strong profitability earns a score of 83/100, reflecting efficient cost management and pricing power. This is up from 14.9% the prior year.
Dexcom Inc's revenue surged 15.6% year-over-year to $4.7B, reflecting rapid business expansion. This strong growth earns a score of 72/100.
Dexcom Inc has a moderate D/E ratio of 1.31. This balance of debt and equity financing earns a leverage score of 40/100.
Dexcom Inc's current ratio of 1.88 indicates adequate short-term liquidity, earning a score of 54/100. The company can meet its near-term obligations, though with limited headroom.
Dexcom Inc converts 23.1% of revenue into free cash flow ($1.1B). This strong cash generation earns a score of 86/100.
Dexcom Inc earns a strong 30.5% return on equity (ROE), meaning it generates $30 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 80/100. This is up from 27.4% the prior year.
Dexcom Inc scores 7.77, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($33.9B) relative to total liabilities ($3.6B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Dexcom Inc passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Dexcom Inc generates $1.72 in operating cash flow ($1.4B OCF vs $836.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Dexcom Inc earns $63.76 in operating income for every $1 of interest expense ($911.8M vs $14.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Dexcom Inc generated $4.7B in revenue in fiscal year 2025. This represents an increase of 15.6% from the prior year.
Dexcom Inc's EBITDA was $1.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 42.3% from the prior year.
Dexcom Inc reported $836.3M in net income in fiscal year 2025. This represents an increase of 45.1% from the prior year.
Dexcom Inc earned $2.09 per diluted share (EPS) in fiscal year 2025. This represents an increase of 47.2% from the prior year.
Cash & Balance Sheet
Dexcom Inc generated $1.1B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 70.8% from the prior year.
Dexcom Inc held $917.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Dexcom Inc's gross margin was 60.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.
Dexcom Inc's operating margin was 19.6% in fiscal year 2025, reflecting core business profitability. This is up 4.7 percentage points from the prior year.
Dexcom Inc's net profit margin was 17.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.7 percentage points from the prior year.
Dexcom Inc's ROE was 30.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.1 percentage points from the prior year.
Capital Allocation
Dexcom Inc invested $599.1M in research and development in fiscal year 2025. This represents an increase of 8.5% from the prior year.
Dexcom Inc spent $500.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 33.3% from the prior year.
Dexcom Inc invested $363.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1.3% from the prior year.
DXCM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0B | $4.7B+15.6% | $4.0B+11.3% | $3.6B+24.5% | $2.9B+18.8% | $2.4B+27.1% | $1.9B+30.5% | $1.5B+43.1% | $1.0B+43.6% | $718.5M+25.3% | $573.3M+42.6% | $402.0M+55.1% | $259.2M+62.0% | $160.0M+60.2% | $99.9M+30.9% | $76.3M |
| Cost of Revenue | $1.9B | $1.9B+16.6% | $1.6B+19.6% | $1.3B+29.9% | $1.0B+33.7% | $768.0M+18.8% | $646.6M+18.8% | $544.5M+48.1% | $367.7M+62.4% | $226.4M+16.2% | $194.9M+57.7% | $123.6M+49.1% | $82.9M+38.4% | $59.9M+12.4% | $53.3M+31.9% | $40.4M |
| Gross Profit | $3.1B | $2.8B+14.9% | $2.4B+6.5% | $2.3B+21.5% | $1.9B+12.1% | $1.7B+31.3% | $1.3B+37.4% | $931.5M+40.3% | $663.9M+34.9% | $492.1M+30.0% | $378.4M+35.9% | $278.4M+57.9% | $176.3M+76.1% | $100.1M+114.8% | $46.6M+29.8% | $35.9M |
| R&D Expenses | $604.0M | $599.1M+8.5% | $552.4M+9.2% | $505.8M+4.5% | $484.2M-6.4% | $517.1M+43.7% | $359.9M+31.6% | $273.5M+37.0% | $199.7M+7.7% | $185.4M+18.8% | $156.1M+13.5% | $137.5M+98.1% | $69.4M+54.9% | $44.8M+17.0% | $38.3M+29.4% | $29.6M |
| SG&A Expenses | $1.4B | $1.3B+0.4% | $1.3B+8.5% | $1.2B+17.6% | $1.0B+24.3% | $810.5M+31.1% | $618.2M+19.9% | $515.7M+19.2% | $432.8M+23.9% | $349.2M+22.0% | $286.2M+44.5% | $198.0M+54.2% | $128.4M+52.5% | $84.2M+31.6% | $64.0M+25.2% | $51.1M |
| Operating Income | $1.1B | $911.8M+52.0% | $600.0M+0.4% | $597.7M+52.8% | $391.2M+47.2% | $265.8M-11.3% | $299.5M+110.5% | $142.3M+176.4% | -$186.3M-338.4% | -$42.5M+33.5% | -$63.9M-11.9% | -$57.1M-165.6% | -$21.5M+25.6% | -$28.9M+48.1% | -$55.7M-24.3% | -$44.8M |
| Interest Expense | $11.1M | $14.3M-4.0% | $14.9M-26.6% | $20.3M+9.1% | $18.6M-1.1% | $18.8M+6.2% | $17.7M-70.6% | $60.3M+165.6% | $22.7M+77.3% | $12.8M+1728.6% | $700K+75.0% | $400K-50.0% | $800K-11.1% | $900K+350.0% | $200K | $0 |
| Income Tax | $280.3M | $252.1M+89.8% | $132.8M-21.4% | $168.9M+240.5% | $49.6M+24.3% | $39.9M+115.8% | -$251.8M-8222.6% | $3.1M+416.7% | $600K-62.5% | $1.6M+128.6% | $700K+600.0% | $100K0.0% | $100K | $0+100.0% | -$1.3M | $0 |
| Net Income | $999.7M | $836.3M+45.1% | $576.2M+6.4% | $541.5M+58.7% | $341.2M+57.3% | $216.9M-60.5% | $549.7M+443.7% | $101.1M+179.5% | -$127.1M-153.2% | -$50.2M+23.5% | -$65.6M-13.9% | -$57.6M-157.1% | -$22.4M+24.8% | -$29.8M+45.3% | -$54.5M-21.9% | -$44.7M |
| EPS (Diluted) | — | $2.09+47.2% | $1.42+9.2% | $1.30+58.5% | $0.82 | $0.53-60.2% | $1.33 | $1.10+176.4% | -$1.44-148.3% | -$0.58 | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
DXCM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.3B-2.2% | $6.5B+3.5% | $6.3B+16.2% | $5.4B+9.3% | $4.9B+15.0% | $4.3B+79.1% | $2.4B+25.0% | $1.9B+111.9% | $904.1M+124.5% | $402.8M+37.9% | $292.0M+58.2% | $184.6M+50.7% | $122.5M+15.6% | $106.0M-12.0% | $120.5M |
| Current Assets | $4.0B-6.2% | $4.3B-2.8% | $4.4B+20.6% | $3.7B-0.4% | $3.7B+7.6% | $3.4B+73.9% | $2.0B+15.9% | $1.7B+128.2% | $744.7M+166.0% | $280.0M+21.1% | $231.3M+58.5% | $145.9M+56.7% | $93.1M+20.0% | $77.6M-25.7% | $104.5M |
| Cash & Equivalents | $917.7M+51.4% | $606.1M+7.0% | $566.3M-11.8% | $642.3M-39.0% | $1.1B+28.7% | $817.6M+83.2% | $446.2M-60.8% | $1.1B+157.5% | $441.5M+367.2% | $94.5M+9.8% | $86.1M+19.9% | $71.8M+66.2% | $43.2M+433.3% | $8.1M+211.5% | $2.6M |
| Inventory | $629.1M+15.9% | $542.6M-3.0% | $559.6M+82.5% | $306.7M-14.2% | $357.3M+52.2% | $234.7M+95.9% | $119.8M+69.4% | $70.7M+56.4% | $45.2M-0.4% | $45.4M+29.0% | $35.2M+120.0% | $16.0M+77.8% | $9.0M+21.6% | $7.4M-9.8% | $8.2M |
| Accounts Receivable | $1.2B+20.9% | $1.0B+3.3% | $973.9M+36.5% | $713.3M+38.7% | $514.3M+20.0% | $428.5M+49.7% | $286.3M+26.3% | $226.7M+68.8% | $134.3M+32.1% | $101.7M+37.2% | $74.1M+74.8% | $42.4M+62.5% | $26.1M+33.8% | $19.5M+56.0% | $12.5M |
| Goodwill | $24.2M+6.1% | $22.8M-9.5% | $25.2M-1.9% | $25.7M-3.0% | $26.5M+37.3% | $19.3M+3.8% | $18.6M-0.5% | $18.7M+54.5% | $12.1M+7.1% | $11.3M+205.4% | $3.7M+15.6% | $3.2M0.0% | $3.2M0.0% | $3.2M | $0 |
| Total Liabilities | $3.6B-18.0% | $4.4B+4.4% | $4.2B+28.7% | $3.3B+12.8% | $2.9B+17.3% | $2.5B+62.9% | $1.5B+20.7% | $1.3B+158.4% | $484.7M+307.3% | $119.0M+68.1% | $70.8M+59.5% | $44.4M+15.6% | $38.4M+32.4% | $29.0M+81.3% | $16.0M |
| Current Liabilities | $2.1B-26.9% | $2.9B+88.4% | $1.6B-15.4% | $1.8B+155.2% | $720.8M+17.4% | $614.1M+70.5% | $360.2M+62.0% | $222.4M+60.1% | $138.9M+35.6% | $102.4M+53.1% | $66.9M+64.8% | $40.6M+26.5% | $32.1M+64.6% | $19.5M+32.7% | $14.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $4.6M-32.4% | $6.8M-2.9% | $7.0M | N/A |
| Total Equity | $2.7B+30.6% | $2.1B+1.6% | $2.1B-3.0% | $2.1B+4.4% | $2.0B+31.6% | $1.6B+75.8% | $882.6M+33.1% | $663.3M+58.2% | $419.4M+47.8% | $283.8M+28.3% | $221.2M+57.8% | $140.2M+66.7% | $84.1M+9.2% | $77.0M-26.3% | $104.5M |
| Retained Earnings | $2.4B+52.3% | $1.6B+56.4% | $1.0B+112.8% | $479.9M+246.0% | $138.7M+277.4% | -$78.2M+88.8% | -$695.7M+12.9% | -$798.9M-18.9% | -$671.8M-8.2% | -$621.0M-11.8% | -$555.4M-11.6% | -$497.8M-4.7% | -$475.4M-6.7% | -$445.6M-13.9% | -$391.1M |
DXCM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.7B | $1.4B+45.6% | $989.5M+32.2% | $748.5M+11.8% | $669.5M+51.3% | $442.5M-7.0% | $475.6M+51.2% | $314.5M+155.3% | $123.2M+33.9% | $92.0M+63.7% | $56.2M+14.7% | $49.0M+107.6% | $23.6M+883.3% | $2.4M+107.3% | -$33.1M-10.0% | -$30.1M |
| Capital Expenditures | $343.7M | $363.5M+1.3% | $358.8M+51.6% | $236.6M-35.1% | $364.8M-6.3% | $389.2M+95.6% | $199.0M+10.6% | $180.0M+168.3% | $67.1M+1.7% | $66.0M+18.5% | $55.7M+67.3% | $33.3M+105.6% | $16.2M+105.1% | $7.9M-16.8% | $9.5M+18.8% | $8.0M |
| Free Cash Flow | $1.4B | $1.1B+70.8% | $630.7M+23.2% | $511.9M+68.0% | $304.7M+471.7% | $53.3M-80.7% | $276.6M+105.7% | $134.5M+139.8% | $56.1M+115.8% | $26.0M+5100.0% | $500K-96.8% | $15.7M+112.2% | $7.4M+234.5% | -$5.5M+87.1% | -$42.6M-11.8% | -$38.1M |
| Investing Cash Flow | $530.7M | $536.0M+358.3% | -$207.5M+59.1% | -$507.2M+2.7% | -$521.5M-141.3% | -$216.1M+78.8% | -$1.0B-0.3% | -$1.0B-626.2% | -$139.8M+3.2% | -$144.4M-158.3% | -$55.9M-8.5% | -$51.5M-206.5% | -$16.8M-180.4% | $20.9M-26.4% | $28.4M+161.2% | -$46.4M |
| Financing Cash Flow | -$2.3B | -$1.7B-129.5% | -$734.8M-130.6% | -$318.6M+42.3% | -$552.5M-5412.5% | $10.4M-98.9% | $912.1M+8424.3% | $10.7M-98.5% | $710.4M+78.0% | $399.1M+4827.2% | $8.1M-51.8% | $16.8M-22.9% | $21.8M+84.7% | $11.8M+15.7% | $10.2M-86.3% | $74.2M |
| Share Buybacks | N/A | $500.0M-33.3% | $750.0M+8.9% | $688.7M+23.5% | $557.7M | $0 | $0 | $0-100.0% | $100.0M | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
DXCM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.1%-0.4pp | 60.5%-2.7pp | 63.2%-1.5pp | 64.7%-3.9pp | 68.6%+2.2pp | 66.4%+3.3pp | 63.1%-1.2pp | 64.4%-4.1pp | 68.5%+2.5pp | 66.0%-3.2pp | 69.3%+1.2pp | 68.0%+5.5pp | 62.6%+15.9pp | 46.7%-0.4pp | 47.0% |
| Operating Margin | 19.6%+4.7pp | 14.9%-1.6pp | 16.5%+3.1pp | 13.4%+2.6pp | 10.9%-4.7pp | 15.5%+5.9pp | 9.6%+27.7pp | -18.1%-12.1pp | -5.9%+5.2pp | -11.2%+3.0pp | -14.2%-5.9pp | -8.3%+9.8pp | -18.1%+37.7pp | -55.8%+3.0pp | -58.7% |
| Net Margin | 17.9%+3.7pp | 14.3%-0.7pp | 14.9%+3.2pp | 11.7%+2.9pp | 8.9%-19.7pp | 28.5%+21.7pp | 6.9%+19.2pp | -12.3%-5.3pp | -7.0%+4.5pp | -11.4%+2.9pp | -14.3%-5.7pp | -8.6%+10.0pp | -18.6%+35.9pp | -54.5%+4.0pp | -58.6% |
| Return on Equity | 30.5%+3.1pp | 27.4%+1.2pp | 26.2%+10.2pp | 16.0%+5.4pp | 10.6%-24.8pp | 35.4%+24.0pp | 11.5%+30.6pp | -19.2%-7.2pp | -12.0%+11.1pp | -23.1%+2.9pp | -26.0%-10.1pp | -16.0%+19.4pp | -35.4%+35.4pp | -70.8%-28.0pp | -42.8% |
| Return on Assets | 13.2%+4.3pp | 8.9%+0.3pp | 8.6%+2.3pp | 6.3%+1.9pp | 4.4%-8.4pp | 12.8%+8.6pp | 4.2%+10.8pp | -6.6%-1.1pp | -5.5%+10.7pp | -16.3%+3.4pp | -19.7%-7.6pp | -12.1%+12.2pp | -24.3%+27.1pp | -51.4%-14.3pp | -37.1% |
| Current Ratio | 1.88+0.4x | 1.47-1.4x | 2.84+0.8x | 1.99-3.1x | 5.11-0.5x | 5.58+0.1x | 5.47-2.2x | 7.64+2.3x | 5.36+2.6x | 2.73-0.7x | 3.46-0.1x | 3.59+0.7x | 2.90-1.1x | 3.98-3.1x | 7.11 |
| Debt-to-Equity | 1.31-0.8x | 2.08+0.1x | 2.03+0.5x | 1.53+0.1x | 1.42-0.2x | 1.59-0.1x | 1.71-0.2x | 1.89+0.7x | 1.16+0.7x | 0.42+0.1x | 0.32+0.3x | 0.030.0x | 0.080.0x | 0.09-0.1x | 0.15 |
| FCF Margin | 23.1%+7.5pp | 15.6%+1.5pp | 14.1%+3.7pp | 10.5%+8.3pp | 2.2%-12.2pp | 14.4%+5.3pp | 9.1%+3.7pp | 5.4%+1.8pp | 3.6%+3.5pp | 0.1%-3.8pp | 3.9%+1.1pp | 2.9%+6.3pp | -3.4%+39.2pp | -42.6%+7.3pp | -49.9% |
Similar Companies
Where Dexcom Inc Ranks
Frequently Asked Questions
What is Dexcom Inc's annual revenue?
Dexcom Inc (DXCM) reported $4.7B in total revenue for fiscal year 2025. This represents a 15.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Dexcom Inc's revenue growing?
Dexcom Inc (DXCM) revenue grew by 15.6% year-over-year, from $4.0B to $4.7B in fiscal year 2025.
Is Dexcom Inc profitable?
Yes, Dexcom Inc (DXCM) reported a net income of $836.3M in fiscal year 2025, with a net profit margin of 17.9%.
What is Dexcom Inc's EBITDA?
Dexcom Inc (DXCM) had EBITDA of $1.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Dexcom Inc's gross margin?
Dexcom Inc (DXCM) had a gross margin of 60.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Dexcom Inc's operating margin?
Dexcom Inc (DXCM) had an operating margin of 19.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Dexcom Inc's net profit margin?
Dexcom Inc (DXCM) had a net profit margin of 17.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Dexcom Inc's return on equity (ROE)?
Dexcom Inc (DXCM) has a return on equity of 30.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Dexcom Inc's free cash flow?
Dexcom Inc (DXCM) generated $1.1B in free cash flow during fiscal year 2025. This represents a 70.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Dexcom Inc's operating cash flow?
Dexcom Inc (DXCM) generated $1.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Dexcom Inc's total assets?
Dexcom Inc (DXCM) had $6.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Dexcom Inc's capital expenditures?
Dexcom Inc (DXCM) invested $363.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Dexcom Inc spend on research and development?
Dexcom Inc (DXCM) invested $599.1M in research and development during fiscal year 2025.
What is Dexcom Inc's current ratio?
Dexcom Inc (DXCM) had a current ratio of 1.88 as of fiscal year 2025, which is generally considered healthy.
What is Dexcom Inc's debt-to-equity ratio?
Dexcom Inc (DXCM) had a debt-to-equity ratio of 1.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Dexcom Inc's return on assets (ROA)?
Dexcom Inc (DXCM) had a return on assets of 13.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Dexcom Inc's Altman Z-Score?
Dexcom Inc (DXCM) has an Altman Z-Score of 7.77, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Dexcom Inc's Piotroski F-Score?
Dexcom Inc (DXCM) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Dexcom Inc's earnings high quality?
Dexcom Inc (DXCM) has an earnings quality ratio of 1.72x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Dexcom Inc cover its interest payments?
Dexcom Inc (DXCM) has an interest coverage ratio of 63.76x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Dexcom Inc?
Dexcom Inc (DXCM) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.